Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries
Bibliographic Data
Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in low- and middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average
Business · Context (archaeology · Control (management · Economic evaluation · Economic growth · Economics · Geography · Government (linguistics · Investment (military · Management · Political science · Psychological intervention · Public economics · Public health · Public sector · Blood Pressure and Hypertension Studies · Health Systems, Economic Evaluations, Quality of Life · Medicine · Nursing · Pharmaceutical Practices and Patient Outcomes
| Citations per year | 0.67 |
|---|---|
| Citation span | 2023 - 2023 (1) |
| Highly cited | No |